Takeda Pharmaceutical Co Ltd Oncology Focused Investor Call Transcript
Hello, everyone, and welcome to Takeda's oncology focused investor call. Before starting I would like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today.
The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings. Please also refer to the important notice in today's presentation material. I would now like to turn the call over to Costa Saroukos, Chief Financial Officer of Takeda.
Hello, everyone. This is Costa Saroukos speaking. Thank you for taking the time to join us today. It gives me great pleasure to welcome you to this investor call focusing on Takeda Oncology.
Many of you will have seen our R&D Day in November last year where we gave an overview on how the R&D transformation we initiated five years ago is starting
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |